

Contents

Preface

xiii

1. Capillary Electrophoresis: A Versatile Technique in Pharmaceutical Analysis	1
<i>Imran Ali, Zeid A. Allothman, Abdulrahman Alwarthan, and Hassan Y. Aboul-Enein</i>	
1.1 Introduction	2
1.2 Theory of Capillary Electrophoresis	2
1.3 Types of Capillary Electrophoresis	5
1.4 Instrumentation	7
1.4.1 Sample Introduction	8
1.4.2 Capillary Electrophoresis Capillary	9
1.4.3 Power Supply	10
1.4.4 Background Electrolyte	11
1.4.5 Detection	11
1.4.5.1 UV/Vis absorbance detectors	12
1.4.5.2 Conductivity detectors	13
1.4.5.3 Amperometric detectors	14
1.4.5.4 Thermo-optical absorbance detectors	15
1.4.5.5 Fluorescence detectors	15
1.4.5.6 Atomic absorption spectroscopy detectors	16
1.4.5.7 Inductively coupled plasma detectors	17
1.4.5.8 Mass detectors	17
1.4.5.9 Miscellaneous detectors	18
1.4.5.10 Indirect detection	19
1.5 Data Integration	20
1.6 Sample Preparation	20
1.7 Method Development and Optimization	21
1.8 Validation of Methods	23
1.9 Applications	24
1.10 Conclusion	45

2. Recent Applications of Chiral Capillary Electrophoresis in Pharmaceutical Analysis	71
<i>José María Saz and María Luisa Marina</i>	
2.1 Introduction	71
2.2 Chiral Selectors Added to BGE for Enantioseparation of Chiral Drugs by CCE	72
2.2.1 Cyclodextrins	73
2.2.2 Macrocyclic Antibiotics	81
2.2.3 Polysaccharides	84
2.2.4 Other Chiral Selectors	85
2.3 Applications of CCE in Pharmaceutical Analysis	87
2.3.1 Analysis of Pharmaceutical Formulations	93
2.3.2 Analysis of Illicit Drugs	96
2.3.3 Analysis of Biological Samples	98
3. A Mini-Review on Enantiomeric Separation of Ofloxacin using Capillary Electrophoresis: Pharmaceutical Applications	117
<i>Suvaradhan Kanchi, Myalowenkosi Sabela, Deepali Sharma, and Krishna Bisetty</i>	
3.1 Introduction	117
3.2 Role of CE in Pharmaceutical Analysis	118
3.3 Challenges Involved in the Enantiomeric Separation of Ofloxacin	119
3.4 Developments in Enantiomeric Separation of Ofloxacin	120
3.4.1 Recent Developments in Enantiomeric Separation of Ofloxacin	121
3.5 Applications of Nanotechnology in Enantiomeric Separation of Ofloxacin	127
3.6 Role of Computational Techniques in Enantiomeric Separation of Ofloxacin	130
3.6.1 Molecular Modeling	135
3.6.2 Molecular Dynamic Simulations	137
3.7 Conclusion	138
4. Nano-Stationary Phases for Capillary Electrophoresis Techniques	147
<i>Chaudhery Mustansar Hussain and Sagar Roy</i>	
4.1 Introduction	148

4.2	Different Types of Nanoparticles/ Nanomaterials	149
4.3	Synthetic Strategies for Immobilization for Nano-Stationary Phases	154
4.4	Evaluation of Nano-Stationary Phases	157
4.5	Conclusion	159
5.	Capillary Electrophoresis Coupled to Mass Spectrometry for Enantiomeric Drugs Analysis	165
	<i>Vítězslav Maier, Martin Švidrnoch, and Jan Petr</i>	
5.1	Enantioseparation of Pharmaceutical Products	166
5.2	Basic Concepts of Enantioseparation by Capillary Electrophoresis	167
5.3	Capillary Electrophoresis with Mass Spectrometry	169
	5.3.1 Electropray Ionization in Hyphenation of CE with MS	170
5.4	Interfacing of CE-ESI-MS	172
	5.4.1 Sheathless Interface	173
	5.4.2 Sheath Liquid Interface	174
	5.4.3 Liquid-Junction Interface	177
5.5	Compatibility of Capillary Electrophoresis and Mass Spectrometry	177
	5.5.1 Basic Principles of Partial Filling Technique	179
5.6	Cyclodextrin as CS for CE-MS Enantioseparation	183
	5.6.1 Experimental Setup without Restrictions of the CD Entering MS Ion Source	184
	5.6.2 Counter-Current Mode for CD-Mediated Enantioseparation by CE-ESI-MS	186
	5.6.3 Partial Filling Technique Employing Neutral Derivatives of CDs	187
	5.6.4 Combination of PFT and Counter- Current Migration for CD-Mediated CE-ESI-MS Enantioseparation	189
5.7	Enantioseparation using MEKC-MS	193
5.8	Crown Ethers Mediated Enantioseparations by CE-MS	200

5.9	Macrocyclic Antibiotics as CS for CE-MS	201
5.10	Non-Aqueous Capillary Electrophoresis-Mass Spectrometry for Enantioseparation	204
5.11	Enantioseparation by CEC-MS	206
5.12	Specifics of Quantitative Analysis of Enantiomers by CE-MS	208
6.	Enantioselective Drug–Plasma Protein-Binding Studies by Capillary Electrophoresis	225
	<i>Laura Escuder-Gilabert, Yolanda Martín-Biosca, Salvador Sagrado, and María José Medina-Hernández</i>	
6.1	Introduction	225
6.2	Plasma Proteins	227
6.3	Capillary Electrophoresis for Enantioselective Protein-Binding Experiments	229
6.3.1	Combination of CE with other Separation Techniques	231
6.3.2	CE for Direct Enantioselective Protein-Binding Evaluation	233
6.4	Experimental Design and Mathematical Models in Protein-Binding Studies	235
6.4.1	Mathematical Models and Deficiencies	235
6.4.2	Experimental Design and Verification of the Assumptions	237
6.4.3	Examples Illustrating the Direct Approach Strategy	240
6.5	Studies on the Application of Capillary Electrophoresis for Evaluating Enantioselective Plasma Protein Binding of Chiral Drugs	242
6.6	Conclusion	251
7.	Clinical Use of Capillary Zone Electrophoresis: New Insights into Parkinson’s Disease	259
	<i>Pedro Rada, Luis Betancourt, Sergio Sacchettoni, Juan Félix del Corral, Hilarión Araujo, and Luis Hernández</i>	
7.1	Introduction	260
7.1.1	Parkinson’s Disease	260
7.1.2	Basal Ganglia Circuitry	261

	7.1.3	In Vivo Monitoring of Brain Molecules	263
7.2		Capillary Zone Electrophoresis	264
	7.2.1	GABA in the Ventrolateral Nucleus of the Thalamus in Two PD Patients	266
	7.2.2	Sample Preparation	267
	7.2.3	Running Conditions	267
7.3		Result	267
	7.3.1	Polyamine Putrescine and Parkinson's Disease	268
	7.3.2	Blood Sampling	269
	7.3.3	Running Conditions	269
	7.3.4	Putrescine Levels in RBCs and Plasma of PD Patients	271
8.		Electrophoretically Mediated Microanalysis for Evaluation of Enantioselective Drug Metabolism	277
		<i>Yolanda Martín-Biosca, Laura Escuder-Gilabert, Salvador Sagrado, and María José Medina-Hernández</i>	
	8.1	Introduction	277
	8.2	Enzymatic Reactions in CE: Electrophoretically Mediated Microanalysis	279
	8.3	Evaluation of Enantioselective Metabolism by EMMA	281
	8.3.1	Study of Stereoselectivity of Flavin-Containing Monooxygenase Isoforms using Cimetidine as Substrate	285
	8.3.2	Characterization of the Enantioselective CYP3A4 Catalyzed N-demethylation of Ketamine	287
	8.3.3	Evaluation of Enantioselective Metabolism of Verapamil and Fluoxetine by the at-Inlet EMMA Mode	292
	8.4	Conclusion	299
9.		Capillary Electrophoresis for the Quality Control of Intact Therapeutic Monoclonal Antibodies	305
		<i>Anne-Lise Marie, Grégory Rouby, Emmanuel Jaccoulet, Claire Smadja, Nguyet Thuy Tran, and Myriam Taverna</i>	
	9.1	Introduction	305
	9.2	Impurities and Drug-Related Substances	308

9.2.1	Process-Related Impurities	308
9.2.2	Product-Related Substances	310
9.2.2.1	Chemical degradations	310
9.2.2.2	Biochemical degradations	315
9.2.2.3	Physical degradations	316
9.3	Identity and Heterogeneity of mAbs	318
9.3.1	Source of Natural Heterogeneity of Proteins: Post-Translational Modifications	318
9.3.2	Identity Control Issues after mAb Compounding	320
9.4	Quality Control of mAbs at Different Stages of Their Production	322
9.4.1	In-process Controls	322
9.4.2	Control of Drug-Related Substances	324
9.4.2.1	Capillary zone electrophoresis	324
9.4.2.2	Capillary gel electrophoresis	329
9.4.2.3	Capillary isoelectric focusing	336
9.4.3	Control of Compounded mAb before Patient Administration	343
9.5	Conclusion	346
10.	Molecular Simulation of Chiral Selector–Enantiomer Interactions through Docking: Antimalarial Drugs as Case Study	363
	<i>Myalowenkosi Sabela, Suvardhan Kanchi, Deepali Sharma, and Krishna Bisetty</i>	
10.1	Introduction	363
10.2	Procedure	368
10.2.1	Experimental Protocol	368
10.2.2	Simulation Protocol	368
10.2.2.1	Ligand and receptor preparation	368
10.2.2.2	Minimization	369
10.2.2.3	Molecular properties	370
10.2.2.4	HOMO-LUMO calculations	370
10.2.2.5	Docking	371
10.2.2.6	Score ligand poses and analysis	371
10.3	Results and Discussion	372

10.3.1	Experimental Enantioseparation	372
10.3.2	Score Ligand Poses and Analysis	374
10.3.3	Analysis of Enantioselective Interaction	376
10.3.4	Enantioresolution	378
10.4	Conclusion and Future Prospect	380

<i>Index</i>		385
--------------	--	-----